# 2025-22131: FDA Issues Draft Guides for Generic Drug Approvals

2025-22131, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-12-05, effective Submit comments by February 3, 2026 to ensure the Agency considers your comment before it begins work on the final version of the guidance. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-22131
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-22131
- Title: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 56161
- Published: 2025-12-05
- Effective: Submit comments by February 3, 2026 to ensure the Agency considers your comment before it begins work on the final version of the guidance.
- Comments close: 2026-02-03
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Issues Draft Guides for Generic Drug Approvals

## Summary

The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by February 3, 2026, before these guides become final. These updates aim to speed up drug approvals and keep costs down for everyone.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product- specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.

## Effects PRIA read

- Draft guidances for generic drug studies: benefit, medium. If you make generic drugs, the FDA posted new draft and revised draft product-specific guidances that give recommendations on how to design bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists specific active ingredients covered (see Tables 1 and 2) and…
- Opportunity to comment by Feb 3, 2026: benefit, low. You may submit electronic or written comments on these draft guidances; to ensure the FDA considers your input before it begins work on the final version, submit comments by February 3, 2026. Instructions for electronic and paper submissions and how to submit confidential material are provided in t…
- FDA says updates aim to speed approvals: benefit, medium. The notice states these updates aim to speed up drug approvals and keep costs down for everyone. If that occurs, consumers could see faster availability of generic drugs and lower drug costs.
- Guidances are non-binding; alternatives allowed: benefit, low. The draft guidances represent the FDA's current thinking but do not establish rights and are not binding. You may use an alternative approach if it satisfies applicable statutes and regulations.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-22131 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/05/2025-22131/product-specific-guidances-draft-and-revised-draft-guidances-for-industry-availability)
- [2025-22131 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-05/pdf/2025-22131.pdf)

## Related
- [Previous: 2025-22129, Sunshine Act Meeting Notice](https://policyrisk.com/federal-register/2025-22129)
- [Next: 2025-22132, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Mee…](https://policyrisk.com/federal-register/2025-22132)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-22131 (as of 2026-06-08).